Insider Buying Celldex Therapeutics Inc President CEO Acquires Shares

CLDX Stock  USD 20.75  1.71  7.61%   
Slightly above 63% of Celldex Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Celldex Therapeutics suggests that many traders are alarmed. Celldex Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Celldex Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Search for Stocks, ETFs, Indices, Insiders, Investing Gurus and Futures on Gurufocus.com.

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

Celldex Therapeutics Current Investor Sentiment

Comfort Level 37

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Celldex Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Celldex Therapeutics.

Celldex Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Celldex Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Celldex Therapeutics Maximum Pain Price Across May 16th 2025 Option Contracts

Celldex Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Celldex Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Celldex Therapeutics' options.

Celldex Therapeutics Fundamental Analysis

We analyze Celldex Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celldex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celldex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Institutions

Shares Owned By Institutions Comparative Analysis

Celldex Therapeutics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Celldex Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Celldex Therapeutics stock to make a market-neutral strategy. Peer analysis of Celldex Therapeutics could also be used in its relative valuation, which is a method of valuing Celldex Therapeutics by comparing valuation metrics with similar companies.

Peers

Celldex Therapeutics Related Equities

MGTXMeiraGTx Holdings   1.95   
0%
15.0%
ALXOAlx Oncology   0.93   
0%
7.0%
AVTEAerovate Therapeutics   0.41   
0%
3.0%
VTYXVentyx Biosciences   0.00   
0%
0%
RVMDRevolution Medicines   0.12   
1.0%
0%
KROSKeros Therapeutics   0.19   
1.0%
0%
TVTXTravere Therapeutics   0.61   
4.0%
0%
DAWNDay One   1.23   
9.0%
0%
DYNDyne Therapeutics   1.32   
10.0%
0%
IDYAIdeaya Biosciences   2.53   
19.0%
0%
ANABAnaptysBio   2.91   
22.0%
0%
IMTXImmatics   3.04   
23.0%
0%
CYTKCytokinetics   4.03   
31.0%
0%
SWTXSpringWorks Therapeutics   4.40   
34.0%
0%
RNAAvidity Biosciences   5.04   
38.0%
0%
CRNXCrinetics Pharmaceuticals   6.35   
49.0%
0%
BCABBioatla   10.05   
77.0%
0%
COGTCogent Biosciences   12.50   
96.0%
0%
EWTXEdgewise Therapeutics   12.93   
100.0%
0%

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.